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Abstract
Background: In 70-80% of cases, neuromyelitis optica (NMO) is associated with highly specific serum auto-
antibodies to aquaporin-4 (termed AQP4-Ab or NMO-IgG). Recent evidence strongly suggests that AQP4-Ab are
directly involved in the immunopathogenesis of NMO.
Objective: To assess the frequency, syndrome specificity, diagnostic relevance, and origin of cerebrospinal fluid
(CSF) AQP4-Ab in patients with NMO spectrum disorders (NMOSD).
Methods: 87 CSF samples from 37 patients with NMOSD and 42 controls with other neurological diseases were
tested for AQP4-Ab in a cell based assay using recombinant human AQP4. Twenty-three paired CSF and serum
samples from AQP4-Ab seropositive NMOSD patients were further analysed for intrathecal IgG synthesis to AQP4.
Results: AQP4-Ab were detectable in 68% of CSF samples from AQP4-Ab seropositive patients with NMOSD, but in
none of the CSF samples from AQP4-Ab seronegative patients with NMOSD and in none of the control samples.
Acute disease relapse within 30 days prior to lumbar puncture, AQP4-Ab serum titres >1:250, and blood-CSF barrier
dysfunction, but not treatment status, predicted CSF AQP4-Ab positivity. A positive AQP4-specific antibody index
was present in 1/23 samples analysed.
Conclusions: AQP4-Ab are detectable in the CSF of most patients with NMOSD, mainly during relapse, and are
highly specific for this condition. In the cohort analysed in this study, testing for CSF AQP4-Ab did not improve the
sensitivity and specificity of the current diagnostic criteria for NMO. The substantial lack of intrathecal AQP4-Ab
synthesis in patients with NMOSD may reflect the unique localisation of the target antigen at the blood brain
barrier, and is important for our understanding of the immunopathogenesis of the disease.
Background
Neuromyelitis optica (NMO) is a rare inflammatory
disorder of the central nervous system (CNS) that pre-
dominantly affects the optic nerves and the spinal cord
[1]. Recent evidence suggests that serum antibodies to
aquaporin-4 (AQP4-Ab or NMO-IgG) are directly
involved in the pathogenesis of NMO [2-8]. Only very
little is known to date about frequency, titres, diagnos-
tic relevance, and pathogenic impact of AQP4-Ab in
the cerebrospinal fluid (CSF) of patients with NMO
and related disorders. Most previous studies investigat-
ing AQP4-Ab did not evaluate CSF,[2,5,9-11] used
assays with low sensitivity,[12] or did not take into
account blood-CSF barrier dysfunction [13]. In particu-
lar, it is still widely unknown whether AQP4-Ab is
produced intrathecally. It is also unclear whether test-
ing of CSF for AQP4-Ab helps to diagnose NMO in
patients negative for serum AQP4-Ab as suggested by
a recent case report [12]. To address these issues, we
tested a large series of consecutive, paired CSF and
serum samples from Caucasian patients with NMO or
its formes frustes, longitudinally extensive transverse
myelitis (LETM) or optic neuritis (ON), as well as
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from controls for AQP4-Ab using a recombinant cell
based assay [14]. In contrast to a previous study,[13]
we controlled for possible disturbances of the blood-
CSF barrier.
Patients and methods
87 CSF samples were analysed, including 45 samples
from 37 patients with NMO spectrum disorders
(NMOSD) from Germany, Austria, and Italy (serum
AQP4-Ab positive in 31, negative in 14 samples) and
42 samples from control patients with multiple sclero-
sis (MS) or other neurological diseases (OND) (Table
1). NMOSD samples included 8 follow-up samples
(AQP4-Ab seropositive in 7, seronegative in 1) from 8
different patients. 29/40 (73%) CSF samples in the
NMOSD group were obtained within 30 days from
onset of the most recent clinical attack (myelitis in 17;
ON in 8; myelitis and ON in 4); in 5 cases the date of
relapse onset was not exactly known. Median time
between onset of relapse and LP was 14 days (range,
2-640), and 8.5 (2-30) if only samples taken within 30
days after relapse onset were considered. 31/38 sam-
ples from control patients with inflammatory disorders
(81.6%) were taken within 30 days after onset of attack;
5 were in remission at time of LP; and 2 had chronic
progressive disease. Median disease duration was 19.4
months (range, 0.1-286) in the NMOSD group and
19.3 (0.1-143.5) in the MS group. Lumbar puncture
was done for diagnostic purposes in all cases. Samples
were stored at -80°C until tested. All samples were
tested in a cell based assay (CBA) as previously
described [14]. This assay was previously demonstrated
to have a sensitivity of 78% for NMO and a specificity
of 100% [14]. From 23 paired CSF and serum samples
sufficient material was available for assessment of the
AQP4-specific antibody index (AI), AIAQP4. Calculation
of AIs allows quantification of antigen-specific
intrathecal antibody synthesis [15,16]. Briefly, AIAQP4
values were calculated as the ratio between the CSF/
serum quotient for AQP4-IgG, QAQP4, and the CSF/
serum quotient for total IgG, QIgG; i.e., AIAQP4 =
QAQP4/QIgG. If AQP4-IgG are produced intrathecally,
QAQP4 would exceed QIgG , resulting in AI values >1.
Usually, values >1.5 are considered as evidence of
intrathecal specific antibody synthesis [15,16]. How-
ever, if titres instead of concentrations are used to cal-
culate the AI, a cut-off of 4 has been recommended
[17]. Reiber’s empiric hyperbolic function Qlim was
applied to control for possible underestimation of
intrathecal specific synthesis due to disturbances of the
blood-CSF barrier function:[18]
Q Qlim(IgG) AIb= + × − ×
− −0 93 6 10 1 7 102 6 3. ( ) .
In case of QIgG > Qlim(IgG), AIAQP4 was calculated as
the ratio between QAQP4 and Qlim(IgG), i.e., AIAQP4 =
QAQP4/Qlim(IgG). For assessment of the AI, serum sam-
ples were tested at 1:10, 1:100, 1:500, 1:1000, and 1:5000
dilutions, and at 1:25, 1:50, 1:62.5, 1:75, 1:125, 1:250,
1:750, 1:1250, 1:1750, 1:2000, 1:2500, 1:3000, 1:4000,
1:6000, 1:7000, 1:8000, 1:9000, and 1:10000 dilutions,
where applicable. CSF samples were tested undiluted, at
1:10 dilution, and, in addition, at dilutions that would
indicate intrathecal production as defined by an elevated
AQP4-AI of >4.
Values for QIgG exceeding the hyperbolic discrimina-
tion line, Qlim, or detection of CSF-restricted oligoclonal
bands (OCB) (data taken from the patient records),
were considered as indicative of intrathecal synthesis of
total IgG (as opposed to AQP4-specific IgG) [16]. The
CSF/serum albumin ratio, QAlb = AlbCSF[mg/l]/Albserum
[g/l], was used to assess the blood-CSF barrier function.
The upper reference limit of QAlb was calculated as 4
+(a/15) with a representing the patient’s age [19].
Table 1 Epidemiological data and sample numbers
Number of
patients
Caucasian Sex ratio, male:
female
Relapsing
course
Paired CSF/serum
samples
Median age at LP
(range)
Untreated at time of
LP (%)
Total 79 72/79 (91) 1:4.6 59/79 (75) 87 40 (15-72) 56/80 (70)
NMOSD 37 32/37 (87) 1:17.5 33/37 (89) 45 41 (17-72) 19/40 (48)†
Controls 42 40/42 (95) 1:2.8 26/42 (62) 42 39 (15-70) 37/40 (93)‡
MS 28 26/28 (92) 1:2.1 26/28 (93) 28 38 (15-69) 2/27
OND 14 14/14
(100)
1:3.7 0/14 (0) 14 45 (20-70) 1/13
Diagnoses in the MS group included relapsing-remitting MS in 26; secondary progressive MS in 1; and primary progressive MS in 1. Diagnoses in the OND group
included acute demyelinating encephalomyelitis in 4; non-longitudinally extensive transverse myelitis in 1; brain stem encephalitis of unknown aetiology in 1;
autoimmune cerebellitis in 1; Herpes simplex virus encephalitis in 1; CNS lymphoma in 1; primary angiitis of the CNS in 1; Behçet’s disease in 1; benign
paroxysmal positional vertigo in 1; hydrocephalus aresorptivus in 1; and spinal disc prolaps in 1. NMO was diagnosed according to reference [39]. LETM was
defined as myelitis extending over three or more segments as demonstrated by magnetic resonance imaging. MS was diagnosed according to reference [40]. †
Treatments in the remaining cases included oral steroids, intravenous methylprednisolone, azathioprine, methotrexate, and cyclo-phosphamide; in 5 cases no
exact data on the treatment status at time of LP were available. ‡ In 2 cases, no exact data on the treatment status was available. LETM = longitudinally
extensive transverse myelitis; MS = multiple sclerosis; NMO = neuromyelitis optica; n.d. = not determined; NMOSD = neuromyelitis spectrum disorders; ON =
optic neuritis; OND = other neurological diseases
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Results
AQP4-Ab CSF status
AQP4-IgG was detected in 21/31 (68%) CSF samples
from AQP4-Ab seropositive NMOSD patients. 0/14 CSF
samples from AQP4-IgG seronegative NMOSD patients
and 0/42 control samples were positive for AQP4-IgG.
No significant difference regarding CSF AQP4-Ab fre-
quency was found between acute relapses of ON (75%)
and myelitis (59%). Detailed results are given in Table 2.
AQP4-Ab serum titres
Serum AQP4-IgG titres were determined in 26/31
NMOSD samples and were higher (median 1:1000;
range, 1:250-1:12.500) in CSF AQP4-IgG-positive
patients (n = 18) than in CSF AQP4-IgG-negative
patients (1:250; 1:10-1:1000; n = 8) (p < 0.002; Mann-
Whitney test). See Figure 1 and Table 2 for details.
Blood-CSF barrier function
Disturbances of the blood-CSF barrier as indicated by
elevated QAlb were present in 11/18 (61%) AQP4-Ab
serum and CSF positive NMOSD samples but only in 1/
8 (13%) of the AQP4-Ab seropositive but CSF-negative
NMOSD samples analysed (p = 0.036; Fisher exact test).
In the AQP4-Ab seronegative group, blood-CSF barrier
dysfunction was present in 6/9 (67%) cases. In the
remaining cases not enough CSF or serum was available
for QAlb determination. No significant correlation
between AQP4-Ab titres and QAlb was found.
Total IgG in the CSF and serum
Evidence for intrathecal synthesis of total IgG as indi-
cated by either CSF-restricted OCBs or elevated QIgG
was present in 32.5% (13/40) NMOSD, and was slightly
more frequent in AQP4-Ab seronegative NMOSD sam-
ples (50%, or 6/12) compared to seropositive samples
(25%, or 7/28). No significant correlation with the
AQP4-Ab CSF status was found; while 100% (7/7) of
the samples with intrathecally produced total IgG that
were obtained from AQP4-Ab seropositive patients were
positive for CSF AQP4-Ab, also 57.1% (12/21) of the
CSF samples from AQP4-Ab seropositive patients with
Table 2 Clinical findings, AQP4-Ab status in serum and CSF, and median AQP4-Ab serum titres in the various disease
groups
Diagnosis No of CSF
samples
Acute attack at time of LP
(%)
AQP4-Ab, serum
(%)
AQP4-Ab, CSF
(%)
Median serum titre (range;
N)
NMOSD 45 29/40 (73) 31/45 (69) 21/45 (47) 1000 (10-12500;26)
NMO 26 16/22 (73) 16/26 (62) 11/26 (42) 1000 (125-7000;12)
LETM 8 6/8 (75) 7/8 (88) 5/8 (63) 250 (62.5-12500;7)
ON 11 7/10 (70) 8/11 (73) 5/11 (45) 250 (10-7000;7)
Relapse 29 29/29 (100) 20/29 (69) 17/29 (59) 1000 (250-12500;20)
Remission 11 0/11 (0) 7/11 (64) 1/11 (9) 187.5 (10-250;6)
AQP4-Ab
seropositive
31 20/31 (65) 31/31 (100) 21/31 (68) 1000 (10-12500;26)
AQP4-Ab
seronegative
14 9/14 (64) 0/14 (0) 0/14 (0) Negative
Controls 42 31/38 (82) 0/42 (0) 0/42 (0) Negative
MS 28 22/28 (79) 0/28 (0) 0/28 (0) Negative
OND 14 9/10 (90)§ 0/14 (0) 0/14 (0) Negative
AQP4-Ab = aquaporin-4 antibody; CSF = cerebrospinal fluid; LETM = longitudinally extensive transverse myelitis; MS = multiple sclerosis; NMOSD = NMO
spectrum disorders; NMO = neuromyelitis optica; ON = optic neuritis; OND = other neurological diseases. § Not applicable in four patients with non-inflammatory
neurological diseases.
Figure 1 Distribution of AQP4-IgG serum titres according to
AQP4-Ab CSF status. AQP4-Ab IgG serum titres were significantly
higher in AQP4-Ab CSF-positive patients.
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neither OCBs nor QIgG elevation harboured AQP4-Ab
(p = n.s.; Fisher exact test). Also, QIgG and AQP4-Ab
titres showed no significant correlation.
AQP4-Ab AI
Intrathecal production (IP) of AQP4-IgG as defined by an
AI > 4 was found in only 1/23 NMOSD samples analysed
(4.3%) (AIAQP4 = 7). This patient had experienced a third
attack of ON 12 days prior to LP (first LETM 10 months
later) and had received high-dose methylprednisolone
until nine days and low-dose steroids until five days prior
to LP. The patient had co-existing acetylcholine recep-
tor-antibody positive myasthenia gravis (treated with pyr-
idostigmine) and thyroglobulin and thyroid peroxidase
antibody positive thyroiditis. Clinical and laboratory find-
ings at time of LP were otherwise unremarkable when
compared to the remaining patients (Table 3). The sam-
ple was positive for OCBs, and QIgG (5.9; Qlim(IgG) = 5.3;
intrathecal IgG fraction, 8.7%) and QAlb (7.2; age-adjusted
upper reference limit = 5.5) were both elevated. A follow-
up sample taken from the same patient one year later
during another relapse of ON and still prior to initiation
of long-term immunosuppression did not show evidence
of AQP4-Ab IP anymore, though the antibody was still
detectable in the CSF. In the remaining cases, not enough
CSF and serum for QIgG and QAlb determination was
available, so that AQP4-AI could not be assessed (n = 5),
or CSF titres that would indicate a positive AQP4-AI
were below 1:1 (n = 3), so that testing was not possible
(all of the latter samples were negative at 1:1 dilution).
Impact of disease activity
17/20 (85%) CSF samples from AQP4-Ab seropositive
NMOSD patients obtained within 30 days after onset of
relapse were AQP4-Ab positive but only 1/7 (14.3%)
taken during remission (p = 0.0017; Fisher exact test, 2-
tailed). Similarly, 17/18 (94.4%) samples positive for CSF
and serum AQP4-Ab were taken during acute relapse;
by contrast, only 3/9 (33.3%) AQP4-Ab CSF-negative
but AQP4-Ab seropositive samples were obtained dur-
ing relapse (p = 0.002; Fisher exact test). The median
serum AQP4-Ab titre of those NMSOD samples taken
during relapse (1:1000; range, 1:250-1:12500; n = 20)
was higher than in NMOSD samples obtained during
remission (1:187.5; 1:10-1:250; n = 6) (p = 0.0008;
Mann-Whitney test). AQP4-Ab serum titres did not dif-
fer markedly between acute relapses of myelitis (median,
1:1000; n = 13) and ON (median, 1:2500; n = 6), and
were relatively high in the only patient with acute
relapse of simultaneous optic neuritis and myelitis
(1:5000). Serum AQP4-Ab titre in the single patient
with evidence for AQP4-Ab IP was 1:1000. IP of total
IgG was found in 7/20 (35%) AQP4-Ab seropositive
samples obtained during relapse but in 0/7 taken during
remission. Disruption of the blood-CSF barrier was
found both with AQP4-IgG seropositive samples taken
during relapse (10/20; 50%) and with some of those
obtained during remission (2/6; 33%). No significant dif-
ferences between acute relapses of myelitis and acute
relapses of ON were found regarding the frequency of
total IgG IP or of blood-CSF barrier disruption.
Impact of disease duration
Median disease duration at time of LP was shorter (24.5
v 4.1 months) in the AQP4-Ab seronegative group (p =
0.056; Mann-Whitney test). Among seropositive
patients, those positive for CSF AQP4-Ab had a longer
disease duration (52.8 vs 19.45 months; p = 0.041). No
correlation between serum titres and disease duration or
time since relapse onset was found.
Impact of treatment status
Median serum AQP4-Ab titres did not differ signifi-
cantly between untreated (n = 12; 1:625; range, 1:62.5-
Table 3 Clinical and laboratory features according to AQP4-AI status
AQP4-Ab AI pos AQP4-Ab AI neg
No of CSF samples 1 22
Sex Female All female
Age 22 40 (14-72)
Diagnosis at time of LP rON* NMO in 11; LETM in 6; ON in 5
IS/IM treatment at time of LP Steroids until 5 d before LP 11/22
Disease duration in months, median 19.4 20.5 (0.1-120)
Acute attack at time of LP Yes 19/22
AQP4-Ab serum titre, median (range) 1:1000 1000 (250-12500)
QIgG, median (range) 5.85 4.8 (1.5-16.1)
Intrathecal synthesis of total IgG Yes 6/22
QAlb, median (range) 7.17 6.7 (3.2-31.1)
Blood-CSF barrier dysfunction Yes 11/22
* Developed NMO 10 months later. AI = antibody index; IS/IM = immunosuppressive/immunomodulatory; NMO = neuromyelitis optica; LETM = longitudinally
extensive transverse myelitis; LP = lumbar puncture; QAlb = albumin CSF/serum ratio; QIgG = IgG CSF/serum ratio; rON = recurrent optic neuritis.
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1:12500) and treated (n = 14; 1:1000; 1:10-1:7000)
NMOSD patients nor did the AQP4-IgG CSF positivity
rate (64.3% and 75%, respectively). The only patient
with positive AIAQP4 had received steroids until five
days before LP.
Longitudinal analysis
In total, 8 follow-up samples from 8 patients with
NMOSD were examined for AQP4-Ab (median latency,
381 days). No patient who was initially positive for
serum AQP4-Ab was negative at follow up; the only
patient negative at first testing was also negative at fol-
low-up. However, the disease status (relapse or remis-
sion) at first and second LP was identical in all cases.
Also, in all cases, CSF was positive for AQP4-Ab in
both samples, if samples were taken during relapse, or
negative, if samples were taken during remission; the
only exception was one AQP4-Ab seropositive sample
that was negative for CSF AQP4-Ab during a relapse of
ON but positive during a relapse of myelitis.
Discussion
In this study we systematically evaluated the frequency
of AQP4-IgG in the CSF and serum of Caucasian
patients with NMOSD. Using a CBA employing recom-
binant human AQP4, we found CSF AQP4-IgG in ~70%
of AQP4-IgG seropositive NMOSD samples, but in
none of the MS or OND controls.
AQP4-IgG CSF positivity was associated with higher
AQP4-IgG serum titres and with dysfunction of the
blood-CSF barrier. Moreover, AQP4-IgG was more fre-
quently detectable during relapse (p = 0.0017). The lat-
ter finding most likely reflects an increase in serum
AQP4-IgG titres during relapse, since no evidence of
intrathecally produced AQP4-IgG was found in almost
all cases analysed. Serum titres were indeed significantly
higher during relapse than in remission in our patients
(median, 1:1000 vs 1:187.5) (p = 0.001), which is in line
with previous studies [13,20]. Interestingly, the cut-off
serum AQP4-IgG titre that predicted CSF AQP4-IgG
positivity (1:250) was similar to that found in Japanese
patients with opticospinal MS [13].
Serum titres >1:250 were associated with acute disease
in all cases, and titres <1:250 with remission. In con-
trast, no clear correlation was found in case the serum
titre was 1:250. It should be mentioned as a caveat,
however, that the number of samples obtained during
remission was relatively low in this study (as LP is
mainly done for acute disease). In a previous study that
included samples obtained over a period of up to five
years, we could demonstrate marked variations over
time regarding AQP4-Ab concentrations during remis-
sion with no general cut-off for relapse induction
(though relapses were always preceded by an relative
increase in AQP4-Ab levels). The latter finding might
indicate differences in AQP4-Ab affinity and specificity
between patients and over time, but inter- and intraindi-
vidual variations regarding T-cell activation, cytokine
levels, or BBB function may also play a role.
Serum AQP4-Ab titres did not differ markedly
between untreated and treated NMOSD patients nor did
the AQP4-IgG CSF-positivity rate. This could be due to
the fact that 11/14 samples from treated patients were
taken during relapse, which was more commonly asso-
ciated with high serum AQP4-Ab titres as well as with
CSF AQP4-Ab.
Intrathecal AQP4-Ab production was present in only
1 out of 23 samples studied (4.3%). This sample was
obtained during an acute relapse of ON. However, 20/
23 AQP4-IgG CSF-positive samples with normal AIAQP4
values were also taken during relapse. AIAQP4 elevation
seems thus not a suitable disease activity marker. The
infrequency of AQP4-IgG IP suggests that in patients
with NMOSD AQP4-Ab producing B cell clones usually
reside in the systemic compartment. CSF AQP4-Ab
might thus reflect passive diffusion of serum AQP4-Ab
into the CSF. Accordingly, Takahashi et al. (2007), in a
study on 12 Japanese patients, found that titres of CSF
AQP4-IgG were almost proportional to serum AQP4-
IgG in NMO, though, as a limitation, that study had not
taken into account possible blood-CSF barrier disrup-
tion [13].
Although intrathecal AQP4-Ab production would then
not be a prerequisite for inflammation in NMO, the sin-
gle patient with a positive AI in our series (as well as a
second recently published case with a slightly elevated
AI[8]) indicates that intrathecal AQP4-Ab production
can occur in NMOSD. However, the rarity with which it
was detected argues against a major pathogenic
function.
Unlike in MS, intrathecal total IgG synthesis in NMO
does not persist over time [21-24]. It is of note that evi-
dence for total IgG IP was present in 35% of seroposi-
tive samples obtained during relapse but in none of the
seropositive samples obtained during remission. In line
with this finding, Melamud et al., in a study so far only
published as abstract, reported intrathecal total IgG
synthesis in 45% of samples obtained in bout versus 0%
in remission [24]. This might explain the low frequency
of intrathecal total IgG production (17-33%) reported in
the literature [1,21-23,25] compared to MS (95-100%).
Similarly, AQP4-Ab might be present in the CSF only
transiently as indicated by our finding of a higher
AQP4-Ab CSF positivity rate during relapse. It is of
note, however, that all eleven samples obtained at
approximately (+/- 8 days) the same time from onset of
relapse than the only AI positive sample (which was
taken at day 12 after relapse onset), showed a negative
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AI, rendering it unlikely that timing issues are of high
importance.
In our cohort, all CSF AQP4-IgG positive samples
were also positive for serum AQP4-IgG, and AQP4-Ab
serum titres were higher than AQP4-Ab CSF titres in all
cases analysed. This would indicate that testing of CSF
for AQP4-Ab in addition to serum AQP4-IgG testing is
of limited benefit. In contrast, Klawiter et al. recently
described three patients positive for AQP4-Ab in the
CSF but not in the serum [12]. However, some con-
straints apply. First, a 1:128 serum dilution was used to
test for AQP4-IgG instead of the standard 1:60 starting
dilution [2,4,26,27]. To our experience from longitudinal
studies in AQP4-IgG positive patients[20], serum sam-
ples may be positive even only at 1:10 dilution, depend-
ing on disease activity status or treatment. Secondly, the
method used to test for AQP4-IgG, immunohistochem-
istry (IHC), has been demonstrated to be less sensitive
compared to recombinant assays [9,13,14]. Thirdly, the
authors discuss that interfering auto-antibodies could
have led to false-negative results, a problem inherent to
the IHC assay but not to the CBA. Therefore, we specu-
late that those samples might have been positive if a
more sensitive and specific assay as well as lower serum
dilutions had been applied.
The concept that pathogenic effects in NMOSD are
predominantly brought about by blood derived AQP4-
Ab is compatible with the unique localisation of the
AQP4 antigen. AQP4 is mainly expressed in the astrocy-
tic endfeet at the glial-endothelial interface [3]. Local
BBB disturbances would thus be sufficient to render the
antigen directly accessible to serum antibodies. In a
recent animal study, induction of BBB damage by pre-
treatment with complete Freund’s adjuvans was in fact
sufficient to cause NMO-like lesions following passive
transfer of AQP4-Ab positive sera [28].
However, severe BBB damage might not even be a
prerequisite for lesion formation. The pial cell layer that
separates the perivascular Virchow-Robin space of larger
vessels from the glia limitans is fenestrated at the level
of the arterioles and is widely missing at the level of
capillaries, venules, and veins. In these areas, the AQP4-
expressing astrocytic endfeet are directly exposed to
antibodies leaving the microvasculature [29]. Impor-
tantly, the perivascular and subpial spaces harbour all
cellular components required to mount local immune
responses [30,31]. Moreover, serum AQP4-IgG could
gain access to the CSF in the absence of BBB damage
via regions of physiologically increased BBB permeability
such as the circumventricular organs or by extracellular
pathways, which provide a quasi-equilibrium between
plasma and the fluids of the CNS [30,32,33]. In an ani-
mal model of NMO, injection of AQP4-Ab positive sera
and human complement into the CSF indeed resulted in
generation of NMO-like lesions in the absence of BBB
disruption or pre-existing CNS inflammation [34]. In
our study, seven patients had in fact normal QAlb values
but suffered from an acute attack, had high serum
AQP4-Ab titres >= 1:250 (median, 1:1000), and were
positive for CSF AQP4-Ab at time of LP. However, as a
limitation, three of those patients were treated at time
of LP, and in three the attack had started already 23, 28
and 30 days before LP. Moreover, QAlb might not be
sufficiently sensitive to reflect locally restricted BBB dis-
ruption, in particular in ON, which was present in 4 of
the 7 patients at time of LP.
Finally, AQP4-Ab itself could induce BBB damage.
Prolonged exposure to AQP4-IgG in the fenestrated
perivascular and subpial spaces could lead to BBB dis-
ruption by gradual local inflammation or AQP4 interna-
lisation, followed by exacerbation of the autoimmune
response [30]. A number of recent in vitro and in vivo
studies revealed that IgG from patients with NMO initi-
ates endocytosis of AQP4, a process which alters the
polarized expression pattern of AQP4 on the plasma
membrane and, as a functional consequence, increases
BBB permeability in vitro [35-37]. In AQP4 knock-out
mice, the lack of AQP4 is mirrored by tight junction
opening in brain microvessels, swelling of perivascular
astrocytic processes, and BBB hyperpermeability [38].
Interestingly, disease activity was linked to higher CSF
AQP4-Ab and to higher serum AQP4-Ab levels in this
study and another,[13] indicating that CSF and/or
serum AQP4-IgG exceeding a threshold value might be
required to induce clinically relevant inflammation.
Conclusion
In summary, our study demonstrates that (1) AQP4-IgG
is detectable in the CSF in most AQP4-IgG seropositive
NMOSD patients but not in that of patients with MS or
OND; (2) that the presence of CSF AQP4-IgG in
patients with NMOSD is positively associated with acute
disease relapse within 30 days prior of LP; AQP4-IgG
serum titres >1:250; and with blood-CSF barrier disrup-
tion; but not with treatment status or the type of acute
clinical disease (myelitis or ON) at time of LP; (3) a lack
of quantitative evidence for intrathecal synthesis of
AQP4-IgG in most NMOSD patients. Our findings
argue against the need to test CSF for AQP4-Ab if the
corresponding serum is negative for the antibody or
AQP4-Ab serum titres are below 1:250. Moreover, our
results suggest that intrathecal production of AQP4-Ab
may not be a prerequisite of disease activity in NMO.
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